University College London - PhD, Biochemical Engineering
University College London and Rensselaer Polytechnic Institute - MEng with Study Abroad, Biochemical Engineering
Dr. Matosevic’s research program focuses on developing new immunotherapies for solid tumors using translational tools to reprogram the therapeutic behavior of natural killer cells and their interaction with the tumor microenvironment by combining approaches in cell therapy, gene engineering, immunology and immunoengineering to (1) Overcome immunometabolic suppression of natural killer cell function in the tumor microenvironment via molecular modulation of their function; (2) Enhance natural killer cell anti-tumor immunity by engineering synthetic genetic constructs that can effectively target solid tumors; (3) Engineer novel cryopreservation platforms devoid of DMSO to improve patient safety upon administration of adoptive natural killer cell therapies.
Tram Ngoc Dao (Graduate Student with Dr. Sandro Matosevic)
Yuning Liu (PULSe rotation PhD student)
Kumar Rishabh (PULSe Fall rotation PhD student)
Xinyu (Cynthia) Wu (Graduate Student with Dr. Sandro Matosevic)
Xue (Shirley) Yao (PULSe Graduate Student with Dr. Sandro Matosevic)
Book Chapter: Matosevic S. Targeting natural killer cells in cancer immunotherapy. In: Systemic Drug Delivery Strategies, Volume 2: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Mansoor Amiji and Lara Milane (Eds), Elsevier, 2022. Chapter 3 pp.63-82
Mamdani H, Matosevic S, Bilal Khalid A, Durm G, Jalal S. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. 2022, Frontiers in Immunology, 10.3389/fimmu.2022.823618.
Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Atallah Lanman N, Bernal-Crespo V, Behymer MM, Knipp GS, Yun Y, Veronesi MC, Sinn AL, Pollok KE, Brutkiewicz R, Nevel KS, Matosevic S. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. 2021, Proceedings of the National Academy of Sciences USA, 118 (45):e2107507118
Lupo K, Moon J, Chambers A, Matosevic S. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions. 2021, Cytotherapy, 23(10):939-952.
Yao X, Matosevic S. Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. 2021, BioDrugs, 35(5):529-545.
Yao X, Matosevic S. Chemokine networks modulating natural killer cell trafficking to solid tumors. 2021, Cytokine and Growth Factor Reviews, 59:36-45. https://doi.org/10.1016/j.cytogfr.2020.12.003.
Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Atallah Lanman N, Bernal-Crespo V, Behymer MM, Knipp GS, Yun Y, Veronesi MC, Sinn AL, Pollok KE, Brutkiewicz R, Nevel KS, Matosevic S. Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastoma. 2020, biorxiv.org/content/10.1101/2020.10.07.330043v1.
Dao T, Utturkar S, Atallah Lanman N, Matosevic S. TIM-3 expression is downregulated on human NK cells in response to cancer targets in synergy with activation. 2020, Cancers, 12(9):2417.
Lupo K, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. 2020, Journal of Hematology & Oncology, 13(76).
Wang J, Matosevic S. Functional and metabolic targeting of natural killer cells to solid tumors. 2020, Cellular Oncology, 43(4):577–600.
Matosevic S. Reprogramming of natural killer cells and their use in immunotherapies of solid tumors. 2020, Immunotherapy, 12(9):605-608.
Yao X, Jovevski JJ, Todd MF, Xu R, Li Y, Wang J, Matosevic S. Nanoparticle-mediated intracellular protection of natural killer cells avoids cryoinjury and retains potent anti-tumor functions. 2020, Advanced Science, 1902938
An S, Ziegler KF, Zhang P, Wang Y, Kwok T, Xu F, Bi C, Matosevic S, Yin P, Li T, Huang F. Axial plane single-molecule super-resolution microscopy of whole cells. 2020, Biomedical Optics Express, 11(1):461-479.
Wang, J., Matosevic, S. NT5E/CD73 as correlative factor of patient survival and natural killer cell infiltration in glioblastoma. 2019, Journal of Clinical Medicine, 8(10), 1526.
Chambers, A., Matosevic, S. Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors. 2019, Frontiers in Molecular Biosciences, 6:60.
Lupo, K., Matosevic, S. Natural killer cells as allogeneic effectors in cancer immunotherapy. 2019, Cancers, 11(6), 769.
Dao, T., Matosevic, S. Immunometabolic responses of natural killer cells to inhibitory tumor microenvironment checkpoints. 2019, Immunometabolism, 2019, 1(1):e190003.
El Assal, R., Abou-Elkacem, L., Tocchio, A., Pasley, S., Matosevic, S., Kaplan, D.L., Zylberberg, C., Demirci, U. Bioinspired preservation of natural killer cells for cancer immunotherapy. Advanced Science, 2019, 6(6):1802045.
Wang, J., Lupo, K., Chambers, A., and Matosevic, S. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. Journal for ImmunoTherapy of Cancer, 2018, 6:136
Chambers, A., Wang, J., Lupo, K., Yu, H., Atallah Lanman, N., and Matosevic, S. Adenosinergic signaling alters natural killer cell functional responses. Frontiers in Immunology, 2018, 9:2533.
Chambers, A., Lupo, K., and Matosevic, S. Tumor-microenvironment-induced immunometabolic reprogramming of natural killer cells. Frontiers in Immunology, 2018, 9:2517.
Matosevic, S. Viral and non-viral engineering of natural killer cells as emerging adoptive cancer immunotherapies. Journal of Immunology Research, 2018, Volume 2018, ID 4054815.
Wang, J., and Matosevic, S. Adenosinergic signaling as a target for natural killer cell immunotherapy. Journal of Molecular Medicine, 2018, 96(9):903-913.
Wang J, Lupo K, Chambers A, Matosevic S. Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. Journal for ImmunoTherapy of Cancer, 2018, 6:136.
Chambers A, Wang J, Lupo K, Yu H, Atallah Lanman N, Matosevic S. Adenosinergic signaling alters natural killer cell functional responses. Frontiers in Immunology, 2018, 9:2533.
Chambers A*, Lupo K*, Matosevic S. Tumor-microenvironment-induced immunometabolic reprogramming of natural killer cells. Frontiers in Immunology, 2018, 9:2517.
Matosevic S. Viral and non-viral engineering of natural killer cells as emerging adoptive cancer immunotherapies. Journal of Immunology Research, 2018, Volume 2018, ID 4054815.
Wang J, Matosevic S. Adenosinergic signaling as a target for natural killer cell immunotherapy. Journal of Molecular Medicine, 2018, 96(9):903-913. *Cover image
Lin-Gibson S, Hanrahan B, Matosevic S, Schnitzler A, Zhang J, Zylberberg C. Points to Consider for Cell Manufacturing Equipment and Components. Cell & Gene Therapy Insights, 2017, 3(10):793-805.
Pasley, Shannon, Zylberberg, Claudia; Matosevic, Sandro. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. Immunology Letters (2017), 192:35-4.
Zylberberg C, Gaskill K, Pasley S, Matosevic S. Engineering liposomal nanoparticles for targeted gene therapy. Gene Therapy, 2017, doi: 10.1038/gt.2017.41.
Zylberberg C and Matosevic S. Bioengineered liposome-scaffold composites as therapeutic delivery systems. Therapeutic Delivery, 2017, 8(6):425-445.
Zylberberg C and Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. 2016, Drug Delivery, 23(9):3319-3329.
Knapinska A, Amar S, He Z, Matosevic S, Zylberberg C, Fields G. Matrix metalloproteinases as reagents for cell isolation. Enzyme and Microbial Technology, 2016,
Matosevic S, Paegel BM. Layer-by-layer cell membrane assembly. Nature Chemistry, 2013, 5:958-963.
Matosevic S, Paegel BM. 2011. Stepwise synthesis of giant unilamellar lipid vesicles on a microfluidic assembly line. Journal of the American Chemical Society, 2011, 133(9):2798-2800.
Matosevic S, Lye GJ, Baganz F. Immobilised enzyme microreactor for the quantification of multi-step bioconversions: Characterisation of a de novo transketolase-omega-transaminase pathway to synthesise chiral amino alcohols. Journal of Biotechnology, 2011, 155(3):320-329
Matosevic S, Szita N, Baganz F. Fundamentals and applications of immobilized enzyme microreactors. J Chem Tech Biotech.86(3):325-334.
Matosevic S, Lye GJ, Baganz F. Development and characterization of a prototype immobilized enzyme microreactor: Quantification of transketolase kinetics. Biotechnology Progress, 2010, 26(1):118-126.
Matosevic S, Micheletti M, Lye GJ, Baganz F. Quantification of kinetics for en-zyme-catalysed reactions: implications for enzyme diffusional limitations at the 10 ml scale. Biotechnology Letters, 2008, 30(6):995-1000.
Venkiteshwaran A, Heider P, Matosevic S, Bogsnes A, Staby A, Sharfstein S, Belfort G. 2007. Optimized Removal of Soluble Host Cell Proteins for the Recovery of met-Human Growth Hormone Inclusion Bodies from Escherichia coli Cell Lysate Using Crossflow Microfiltration. Biotechnology Progress, 23(3):667-672.
Google Scholar profile: https://scholar.google.com/citations?user=u0MWS_oAAAAJ&hl=en